MTOR and acute myeloid leukemia: Moreover, FMS-Like Tyrosine kinase 3 (FLT3) mutations which are found at a frequency of 25–355 in AML, activate PI3K/AKT in the cells [60, 61], resulting in the activation of Mammalian Target Of Rapamycin (mTOR) and subsequently the accumulation of HIF-1α in the cells [62, 63].